Spyre reports Q2 net loss $36.2M; cash $1.15B; positive Phase 2 data for SPY001/SPY002 in UC

Spyre Therapeutics, Inc.

2026-Q2 EPS reported -$1.09

Net loss of $36.2M in Q2 2026 vs $36.7M in Q2 2025; R&D expenses rose to $65.5M from $40.1M.
Cash, equivalents, and marketable securities of $1,145.3M as of June 30, 2026; raised $435.2M net in April 2026 public offering.
SPY001 achieved 40% clinical remission and 51% endoscopic improvement; SPY002 achieved 33% and 42%, respectively, in Part A of SKYLINE UC trial.
Enrollment completed for Phase 2 SKYWAY basket trial in RA, PsA, axSpA; RA data expected September 2026, PsA/axSpA data in Q4 2026.
Recognized $40.0M gain on milestone from sale of priority review voucher related to legacy asset pegzilarginase.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.